NCT06775379Phase 3Terminated

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Study sponsor: Xenon Pharmaceuticals Inc. · XENE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-10-28Actual
Enrollment · participants357Actual
Source updated2026-11-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 450 participants (planned). After: 357 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Oct 2026. After: 28 Oct 2026.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

· 2 fields changed

Primary completion date changed

Before: Aug 2026. After: Oct 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source